A NEW ERA IN TREATING HEMOPHILIA A AND B
By HemoAB Symposium
Date and time
Thursday, April 14, 2016 · 12:15 - 1:45pm CDT
Location
Sheraton Chicago Hotel & Towers
301 East North Water St Room: Ballrooms 1 and 2 Chicago, ILDescription
OVERVIEW
The recent introduction of new bioengineered Factor VIII and Factor IX replacement therapies with longer half-lives are expected to have profound implications on prophylaxis treatment regimens on patients being treated for hemophilia. The decreased frequency of infusions with these bioengineered therapies is expected to facilitate individualized treatment plans that will incorporate patient-specific targeted trough levels, reducing risk of breakthrough bleeds. Prophylaxis can protect against joint disease and allow a hemophilia patient to live a normal life with an average life expectancy, but the key to its effectiveness is early implementation and good adherence. This live educational activity will review the principles of pharmacokinetic-based factor replacement therapy, including its potential advantages and disadvantages as prophylaxis versus on-demand therapy. Because adherence is the cornerstone of effective prophylaxis, effective methods to measure and increase adherence that can be practically implemented in a busy clinical setting will be discussed.
GOAL
This live case-based educational activity will provide clinicians who treat patients with hemophilia A or B with up-to-date information on pharmacokinetic-based factor replacement when used as prophylaxis and, because prophylaxis relies on optimal adherence, practical methods to measure and address adherence issues.
INTENDED AUDIENCE
This activity has been designed to meet the needs of adult and pediatric physicians in hematology settings, as well as other appropriate healthcare providers (including orthopedists, dentists, nurse practitioners and physicians’ assistants) who care for patients with hemophilia. There are no prerequisites.
LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
- DESCRIBE the role of pharmacokinetic-based therapy in the management of children and adults with hemophilia.
- IMPLEMENT PK-based therapy for patients with hemophilia.
- DESCRIBE clinician interventions to identify and address medication nonadherence in the management of patients with hemophilia.
- INCORPORATE rapid methods to measure adherence to therapy in the management of patients of hemophilia.
ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AGENDA
12:15 – 12:25 PM Conference Goals and Preassessment
John J. Strouse, MD, PhD
John J. Strouse, MD, PhD
12:25 – 12:55 PM Pharmacokinetic Based Factor Replacement to Optimize Prophylactic and
Therapeutic Treatment of Hemophilia
Stacy E. Croteau, MD, MMS
Stacy E. Croteau, MD, MMS
12:55 – 1:25 PM Clinician Interventions to Improve Adherence to Hemophilia Treatment
Michelle N. Eakin, PhD
Michelle N. Eakin, PhD
1:25 – 1:45 PM Q & A and Educational Outcomes Activity
John J. Strouse, MD, PhD
John J. Strouse, MD, PhD
This schedule is subject to change.
PARTICIPATING FACULTY
John J. Strouse, MD, PhD (Course Director)
Assistant Professor of Pediatrics and Medicine
Johns Hopkins University School of Medicine
Division of Pediatric Hematology
Baltimore, Maryland
Stacy E. Croteau, MD, MMS
Instructor in Pediatrics
Harvard Medical School
Associate Director
Boston Hemophilia Center
Boston, Massachusetts
Michelle N. Eakin, PhD
Assistant Professor
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
Assistant Professor of Pediatrics and Medicine
Johns Hopkins University School of Medicine
Division of Pediatric Hematology
Baltimore, Maryland
Stacy E. Croteau, MD, MMS
Instructor in Pediatrics
Harvard Medical School
Associate Director
Boston Hemophilia Center
Boston, Massachusetts
Michelle N. Eakin, PhD
Assistant Professor
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
POLICY ON FACULTY AND PROVIDER DISCLOSURE
It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosures will be made in the course materials.
PHYSICIAN PAYMENTS SUNSHINE ACT
Please note: The Physician Payments Sunshine Act was enacted by Congress to increase public awareness of financial relationships between drug and medical device manufacturers and physicians. In compliance with the requirements of this Act, the commercial supporter/s of this activity may require the Johns Hopkins University School of Medicine to report certain professional information (such as name, address, National Provider Identifier, and State License #) of physician attendees who receive complimentary food and beverage in conjunction with a CME activity. The commercial supporter is required to submit the collected data to the Centers for Medicare and Medicaid Services which will then publish the data on its website.
AMERICANS WITH DISABILITIES ACT (ADA)
The Johns Hopkins University School of Medicine and ASiM fully complies with the legal requirements of the ADA and the rules and regulations thereof.
FEE INFORMATION
There is no fee for this educational activity.